Alterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy

Reuters

2025/07/28

<a href="https://laohu8.com/S/ATH.AU">Alterity Therapeutics</a> Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy

Alterity Therapeutics Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy $(MSA)$. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554749516"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554749516\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554749516?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 08:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554749516","market":"fut","top_or_hot":-1,"title":"Alterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATH.AU\">Alterity Therapeutics</a> Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy <a href=\"https://laohu8.com/S/MSA\">$(MSA)$</a>. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-28 08:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATH.AU\">Alterity Therapeutics</a> Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy <a href=\"https://laohu8.com/S/MSA\">$(MSA)$</a>. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATH.AU","symbol_name":"ALTERITY THERAPEUTICS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL64s93X:1","article_id":"2554749516","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554749516","pubTimestamp":1753661864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alterity Therapeutics Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy . The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATH.AU":"ALTERITY THERAPEUTICS LTD","BK7067":"生物科技"},"translate_title":"Alterity Therapeutics宣布ATH434治疗多系统萎缩的2期试验取得积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATH.AU":0.9},"content_text":"Alterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy\n    \n\n        Alterity Therapeutics Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy $(MSA)$. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}